The expanding role of fish models in understanding non-alcoholic fatty liver disease
- PMID: 23720231
- PMCID: PMC3701210
- DOI: 10.1242/dmm.011981
The expanding role of fish models in understanding non-alcoholic fatty liver disease
Erratum in
- Dis Model Mech. 2014 Mar;7(3):409
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a condition in which excessive fat accumulates in the liver of an individual who has not consumed excessive alcohol. Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, can progress to hepatic cirrhosis and/or hepatocellular carcinoma (HCC). NAFLD is considered to be a hepatic manifestation of metabolic syndrome, and its incidence has risen worldwide in lockstep with the increased global prevalence of obesity. Over the last decade, rodent studies have yielded an impressive list of molecules associated with NAFLD and NASH pathogenesis. However, the identification of currently unknown metabolic factors using mammalian model organisms is inefficient and expensive compared with studies using fish models such as zebrafish (Danio rerio) and medaka (Oryzias latipes). Substantial advances in unraveling the molecular pathogenesis of NAFLD have recently been achieved through unbiased forward genetic screens using small fish models. Furthermore, these easily manipulated organisms have been used to great advantage to evaluate the therapeutic effectiveness of various chemical compounds for the treatment of NAFLD. In this Review, we summarize aspects of NAFLD (specifically focusing on NASH) pathogenesis that have been previously revealed by rodent models, and discuss how small fish are increasingly being used to uncover factors that contribute to normal hepatic lipid metabolism. We describe the various types of fish models in use for this purpose, including those generated by mutation, transgenesis, or dietary or chemical treatment, and contrast them with rodent models. The use of small fish in identifying novel potential therapeutic agents for the treatment of NAFLD and NASH is also addressed.
Figures


Similar articles
-
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2012 May 21;18(19):2300-8. doi: 10.3748/wjg.v18.i19.2300. World J Gastroenterol. 2012. PMID: 22654421 Free PMC article. Review.
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
-
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525. Int J Mol Sci. 2020. PMID: 32102237 Free PMC article. Review.
-
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17. Indian J Med Res. 2019. PMID: 31115369 Free PMC article. Review.
-
Preclinical models of non-alcoholic fatty liver disease.J Hepatol. 2018 Feb;68(2):230-237. doi: 10.1016/j.jhep.2017.10.031. Epub 2017 Nov 9. J Hepatol. 2018. PMID: 29128391 Free PMC article. Review.
Cited by
-
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Dec 28;20(48):18070-91. doi: 10.3748/wjg.v20.i48.18070. World J Gastroenterol. 2014. PMID: 25561778 Free PMC article. Review.
-
Inositol Inclusion Affects Growth, Body Composition, Antioxidant Performance, and Lipid Metabolism of Largemouth Bass (Micropterus salmoides).Aquac Nutr. 2024 Jan 19;2024:9944159. doi: 10.1155/2024/9944159. eCollection 2024. Aquac Nutr. 2024. PMID: 38283889 Free PMC article.
-
High-fat diet in early life triggers both reversible and persistent epigenetic changes in the medaka fish (Oryzias latipes).BMC Genomics. 2023 Aug 21;24(1):472. doi: 10.1186/s12864-023-09557-1. BMC Genomics. 2023. PMID: 37605229 Free PMC article.
-
Ability of prebiotic polysaccharides to activate a HIF1α-antimicrobial peptide axis determines liver injury risk in zebrafish.Commun Biol. 2019 Jul 25;2:274. doi: 10.1038/s42003-019-0526-z. eCollection 2019. Commun Biol. 2019. PMID: 31372513 Free PMC article.
-
Interaction Mechanisms Between Major Depressive Disorder and Non-alcoholic Fatty Liver Disease.Front Psychiatry. 2021 Dec 13;12:711835. doi: 10.3389/fpsyt.2021.711835. eCollection 2021. Front Psychiatry. 2021. PMID: 34966296 Free PMC article.
References
-
- Amali A. A., Rekha R. D., Lin C. J., Wang W. L., Gong H. Y., Her G. M., Wu J. L. (2006). Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J. Biomed. Sci. 13, 225–232 - PubMed
-
- Aoki K., Matsudaira H. (1977). Induction of hepatic tumors in a teleost (Oryzias latipes) after treatment with methylazoxymethanol acetate: brief communication. J. Natl. Cancer Inst. 59, 1747–1749 - PubMed
-
- Balkan J., Doğru-Abbasoğlu S., Kanbağli O., Cevikbaş U., Aykaç-Toker G., Uysal M. (2001). Taurine has a protective effect against thioacetamide-induced liver cirrhosis by decreasing oxidative stress. Hum. Exp. Toxicol. 20, 251–254 - PubMed
-
- Balthasar N., Dalgaard L. T., Lee C. E., Yu J., Funahashi H., Williams T., Ferreira M., Tang V., McGovern R. A., Kenny C. D., et al. (2005). Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123, 493–505 - PubMed
-
- Boorman G. A., Botts S., Bunton T. E., Fournie J. W., Harshbarger J. C., Hawkins W. E., Hinton D. E., Jokinen M. P., Okihiro M. S., Wolfe M. J. (1997). Diagnostic criteria for degenerative, inflammatory, proliferative nonneoplastic and neoplastic liver lesions in medaka (Oryzias latipes): consensus of a National Toxicology Program Pathology Working Group. Toxicol. Pathol. 25, 202–210 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases